Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mucofalk is a bulk-forming laxative and phytopharmaceutical product whose active ingredient is the ground husks of Plantago ovata seeds (also known as ispaghula or Indian psyllium). It acts by absorbing water in the intestine, swelling to increase stool mass and volume. This promotes peristalsis and facilitates easier bowel movements. Mucofalk is used for chronic constipation, conditions requiring soft stools (such as anal fissures, hemorrhoids, post-rectal surgery), supportive treatment of diarrhea of various causes, irritable bowel syndrome (IBS), and as an adjunct in hypercholesterolemia. The mechanism relies on its high content of soluble dietary fiber that binds water and forms a lubricating gel-like mass in the gut[2][3][4][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mucofalk.